Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
IPO Year:
Exchange: NASDAQ
Website: athersys.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/19/2021 | $1.25 | Buy → Neutral | B of A Securities |
| 11/19/2021 | Buy → Neutral | BofA Securities |
Athersys, Inc. (OTC:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and Recent Corporate and Operational Highlights: Announced results of a blinded interim analysis of Phase 3 MASTERS-2 clinical trial studying MultiStem for treatment of ischemic stroke indicating additional patients would need to be added to the trial to achieve statistical significance with a primary endpoint of mRS Shift Analysis at Day 365. Completed warrant exercise inducement generating gross proceeds of $3.
Athersys, Inc. (NASDAQ:ATHX), ("Athersys" or the "Company") a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from HEALIOS K.K. ("Healios") under the acute respiratory distress syndrome ("ARDS") global license. On October 11, 2023, Athersys entered into a warrant exercise inducement offer letter (the "Inducement Letter") with a holder of certain existing warrants ("Holder") to receive new warrants
The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company's ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary endpoint of mRS Shift analysis at Day 365. There were no safety issues identified. Because the s
Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, and Multipotent Adult Progenitor Cell (MAPC®) technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with Ardent Animal Health (Ardent). Ardent is a privately held veterinary biotechnology company developing regenerative medicine and cancer therapies for animals. Under the terms of the agreement, Athersys will receive an initial fee from Ardent in exchange for an exclusive license to Athersys' Multipotent Adult Progenitor Cell (MAPC®) technology for non-human mammal applications in the Uni
Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces changes to its Board of Directors following the Company's recent 2023 Annual Meeting of Stockholders. Current Director Jane Wasman, JD, has been appointed Board Chair, effective September 28, 2023. Ms. Wasman has served as a Director of the Company since November 2020, currently serving as Chair of Athersys' Audit Committee and previously serving as Chair of its Nominations, Governance & Compliance Committee. "We are delighted that Jane will now be chairing Athersys' board. She brings a wealth of expertise in strategic, operational, business developm
Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces that Dr. Samuel Tingle, a surgeon and PhD candidate at Newcastle University in Newcastle upon Tyne, England, has received grant funding from the UK Research and Innovation's Medical Research Council to explore the potential use of Athersys' MultiStem cellular therapy during machine perfusion prior to kidney transplantation. Machine perfusion refers to a technology used for limiting the damaging effects of removing and transporting kidneys prior to transplantation. It involves a machine that pumps fluid around the organ while it is outs
Athersys, Inc. (NASDAQ:ATHX), today announced the pricing of its "reasonable best efforts" public offering of 10,937,500 shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.32 per share. The Company further agreed to issue to the investors Series A Warrants to purchase up to an aggregate of 10,937,500 shares of common stock and Series B Warrants to purchase up to an aggregate of 10,937,500 shares of common stock. The Series A and Series B Warrants will have an exercise price of $0.32 per share, will be exercisable immediately following the date of issuance and will expire in five years and one and a half years, respectively. The closing of the of
Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and six months ended June 30, 2023 and provided a business update. Second Quarter 2023 and Recent Corporate and Operational Highlights: Nominated healthcare executive and strategy consultant Neema Mayhugh, Ph.D. to the Company's Board of Directors Surpassed two-thirds patient enrollment in the MASTERS-2 clinical trial with MultiStem for ischemic stroke Completed Memorandum of Understanding with Healios to provide consulting support with PMDA to explore the feasibility of adding Japanese patients t
Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings. Dr. Mayhugh currently serves as the Founder and Managing Partner of Wave Strategy, a consultancy focused on the rapid commercialization of healthcare innovations. Under her leadership, Wave Strategy has bridged early-stage t
Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke. Date
8-K - ATHERSYS, INC / NEW (0001368148) (Filer)
25-NSE - ATHERSYS, INC / NEW (0001368148) (Subject)
8-K - ATHERSYS, INC / NEW (0001368148) (Filer)
424B3 - ATHERSYS, INC / NEW (0001368148) (Filer)
EFFECT - ATHERSYS, INC / NEW (0001368148) (Filer)
S-1/A - ATHERSYS, INC / NEW (0001368148) (Filer)
10-Q - ATHERSYS, INC / NEW (0001368148) (Filer)
S-1 - ATHERSYS, INC / NEW (0001368148) (Filer)
8-K - ATHERSYS, INC / NEW (0001368148) (Filer)
8-K - ATHERSYS, INC / NEW (0001368148) (Filer)
B of A Securities downgraded Athersys from Buy to Neutral and set a new price target of $1.25
BofA Securities downgraded Athersys from Buy to Neutral
4 - ATHERSYS, INC / NEW (0001368148) (Issuer)
4 - ATHERSYS, INC / NEW (0001368148) (Issuer)
4 - ATHERSYS, INC / NEW (0001368148) (Issuer)
4 - ATHERSYS, INC / NEW (0001368148) (Issuer)
4 - ATHERSYS, INC / NEW (0001368148) (Issuer)
3 - ATHERSYS, INC / NEW (0001368148) (Issuer)
4 - ATHERSYS, INC / NEW (0001368148) (Issuer)
4 - ATHERSYS, INC / NEW (0001368148) (Issuer)
4 - ATHERSYS, INC / NEW (0001368148) (Issuer)
4 - ATHERSYS, INC / NEW (0001368148) (Issuer)
Healthcare Executive and Strategy Consultant Brings Considerable Innovation, Commercialization and Entrepreneurial Expertise Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Neema Mayhugh, PhD to its Board of Directors. Dr. Mayhugh is an executive with more than 20 years of experience in healthcare consulting, industry, academic and hospital settings. Dr. Mayhugh currently serves as the Founder and Managing Partner of Wave Strategy, a consultancy focused on the rapid commercialization of healthcare innovations. Under her leadership, Wave Strategy has bridged early-stage t
Believes the Stern-Controlled Board's Decision to Challenge Our Special Meeting Demand – Without Any Valid Justification – Reinforces the Need for Objective and Independent Perspectives in the Boardroom Contends the Company is Making Misleading Claims About Murchinson to Distract from Mr. Stern Having Presided Over a More Than 77% Share Price Decline Since Becoming Chairman Puts Forward Proposals to Remove Four Incumbents and Appoint Two Highly Qualified, Independent Director Candidates with Sorely Needed Capital Allocation Acumen and Corporate Governance Expertise Sees a Clear Opportunity to Optimize Nano Dimension's Overcapitalized Balance Sheet, Explore Strategic Options to Maximize V
Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today the appointment of Joseph "Joe" Nolan to its Board of Directors, effective January 4, 2023. Mr. Nolan is an experienced biotechnology and pharmaceutical executive who currently serves as Chief Executive Officer of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent. "Joe is a strong addition to our Board, bringing more than 30 years of experience managing high-value global pipelines, launching multiple successful drugs and optimizing large-scale commercial operations. His understanding of th
Brings Operational Excellence and Financial Experience to Leadership Team Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces today its engagement with Ankura Consulting Group, LLC and the appointment of Kasey Rosado as the Company's interim Chief Financial Officer. Ms. Rosado joins the Company subsequent to its recent restructuring and will support management on all aspects of the Company's financial strategy. Ms. Rosado brings to Athersys more than 18 years of financial, operational and leadership experience. As Senior Managing Director at Ankura, Ms. Rosado provides advisory support for dozens of c
Camardo to lead Company's transition to a commercial-stage company Athersys, Inc. (NASDAQ:ATHX), an international, late-stage, regenerative medicine company, announced today the appointment of Daniel A. Camardo as the Company's Chief Executive Officer, effective February 14, 2022. Mr. Camardo is a senior pharmaceutical and biotech executive with more than 25 years of commercial leadership experience. As Chief Executive Officer, he will lead Athersys forward to complete the development, approval, launch, and commercialization of the Company's MultiStem® (invimestrocel) cell therapy for the treatment of serious conditions, including ischemic stroke. Mr. Camardo will also join the Athersys Bo
SC 13G - ATHERSYS, INC / NEW (0001368148) (Subject)
SC 13G/A - ATHERSYS, INC / NEW (0001368148) (Subject)
SC 13D/A - ATHERSYS, INC / NEW (0001368148) (Subject)
SC 13D/A - ATHERSYS, INC / NEW (0001368148) (Subject)
SC 13G - ATHERSYS, INC / NEW (0001368148) (Subject)
Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss timing to conduct an interim analysis with MASTERS-2, a Phase 3 pivotal trial of MultiStem treatment in ischemic stroke. Date
Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress and discuss upcoming milestones supporting the pivotal Phase 3 ischemic stroke trial, MASTERS-2. Date April 20, 2023 Time
Athersys, Inc. (NASDAQ:ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress, upcoming milestones and vision for the year. Date February 14, 2023 Time 11:00 a.m. (Eastern Time) Live webcast re
Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today that it intends to file its quarterly report on Form 10-Q for the three months ended September 30, 2022 with the U.S. Securities and Exchange Commission (SEC) after market close on Monday, November 14, 2022, issue a news release reporting those financial results and recent business highlights before market open on Tuesday, November 15, 2022, and hold a conference call at 11:00 a.m. Eastern Time on Tuesday, November 15, 2022. The company is rescheduling the reporting of its third quarter 2022 financial results in order to provide sufficient time
Athersys, Inc. (NASDAQ:ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results. Members of the management team will host the call as follows: Date November 10, 2022 Time 4:30 p.m. (Eastern Time) Live webcast registration Webcast link Phone registration Call registration link We encourage shareholders to register and listen to the call using the webcast link above. Once registered, you will receive an email containing the toll-free number, a direct entry passcode and a registrant ID. Please send questions you would like management to address in advance of the call to
Athersys, Inc. (NASDAQ:ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert "Willie" Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the company's accomplishments since its recently announced restructuring. Date October 6, 2022 Time 4:00 p.m. (Eastern Time) Live webcast registration Webcast link Phone registration
Corporate restructuring underway and MASTERS-2 clinical trial prioritized Conference call begins at 4:30 p.m. Eastern time today Athersys, Inc. (NASDAQ:ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate Restructuring Implemented a restructuring of our organization with the intention of significantly reducing expenses, conserving cash, improving focus of the Company's activities and becoming more attractive to potential financial and strategic partners. Reduction in workforce of up to 70% including changes to leadership team Reduced size of B
Athersys, Inc. (NASDAQ:ATHX) will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: Date August 11, 2022 Time 4:30 p.m. (Eastern Time) Live webcast registration Webcast link Phone registration Call registration link We encourage shareholders to listen using the webcast link above. If you would like to dial in using the phone to ask a question, please register for the conference call ahead of time using the call registration link abo
Workforce reduction up to 70% Conference call today at 5:00 p.m. ET Athersys, Inc. (NASDAQ:ATHX) today announced a corporate restructuring plan to reduce costs and prioritize its lead clinical programs. In connection with the restructuring, the Company is reducing its workforce up to 70%, with the majority of the reduction expected to be completed by the end of June 2022. Reducing the workforce is an initial step the Company is taking to reduce its cost structure and become more attractive to both financial and strategic partners. As part of the restructuring plan, the Company also announced changes to its executive team. Mr. William (B.J.) Lehmann, President and Chief Operating Officer,
TREASURE topline results show evidence of therapeutic impact Study preliminary results analyses indicate good potential for favorable results in Athersys' MASTERS-2 study Conference call today at 8:30 a.m. ET Athersys, Inc. (NASDAQ:ATHX) announced today that its partner, HEALIOS K.K. (Healios), has reported topline results for its Japan ischemic stroke study, TREASURE. The randomized, double-blind placebo-controlled study included patients with moderate to moderate-severe ischemic stroke (baseline NIHSS 8-20) with administration of a single dose of MultiStem® cells (invimestrocel) or placebo by intravenous infusion within 18-36 hours of the event. The trial enrolled 206 patients and was